Lung Cancer

Original Research, Lung Cancer, Immunotherapy, Adverse Events

Outcomes of Early Versus Delayed Initiation of Immunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer

Matthew Warrick, PharmD, BCPS, BCOP; Rebecca Worden, PharmD, BCOP; Carly Kesler, PharmD, BCOP; Katie Murto, PharmD, BCOP; Amanda Edwards, PharmD, BCOP, CPP

Online First

Original Research, Checkpoint Inhibitors, Adverse Events, Lung Cancer

Impact of Hyperglycemia During Immune Checkpoint Inhibitor Treatment for Advanced Non–Small Cell Lung Cancer: A Retrospective, Single-Center Study

Allison L. Thurman, PharmD; Susan Storey, PhD, RN, ACONS, FCNS; David J. Reeves, PharmD, BCOP

Case Reports, Lung Cancer, Screening, Tyrosine Kinase Inhibitor

The Presence of De Novo EGFR T790M Mutation in a Tyrosine Kinase Inhibitor–Naïve Patient with Lung Adenocarcinoma: Case Report and Review of the Literature

Jessica Katiaj, PharmD; Rosemary Boshar, PharmD; Maryann R. Cooper, PharmD, BCOP; Gerald Gehr, MD

Case Reports, Lung Cancer, Tyrosine Kinase Inhibitor

Third-Line Tyrosine Kinase Inhibitor Therapy Results in 16-Year Remission in a Patient with Stage IV Non–Small-Cell Lung Cancer

Carrie L. Barnhart, PharmD, BCOP, and David F. Christianson, MD

Lung Cancer

2022 Midyear Review: Non–Small-Cell Lung Cancer

Meeting Highlights Online Only

AACR Highlights, Lung Cancer

First-Line Sotorasib Shows Long-Lasting Responses in Metastatic NSCLC with KRAS Mutation

FDA Updates, Lung Cancer, Checkpoint Inhibitors

Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC

Lung Cancer

Severe Adverse Events from Immune Checkpoint Inhibitor Therapy a Rare Concerning Side Effect

Lung Cancer

KRASᴳ¹²ᶜ Mutation–Positive Advanced NSCLC

Lung Cancer

CodeBreaK 100 Trial Results Demonstrate Sotorasib Conveys Clinical Benefit Across NSCLC Patient Subgroups

Page 1 of 12
Results 1 - 10 of 117

Subscribe Today!

I'd like to receive: